Antiphospholipid antibody syndrome and LVAD: What are the chances? A case report and literature review

Vincenzo Tarzia; Chiara Tessari; Assunta Fabozzo; Chiara Cavalli; Chiara Pagnin; Biancarosa Volpe; Tomaso Bottio; Gino Gerosa

doi:10.1177/0391398821996726

Antiphospholipid antibody syndrome and LVAD: What are the chances? A case report and literature review

Int J Artif Organs. 2022 Feb;45(2):235-238. doi: 10.1177/0391398821996726. Epub 2021 Mar 18.

Authors

Vincenzo Tarzia¹, Chiara Tessari¹, Assunta Fabozzo¹, Chiara Cavalli², Chiara Pagnin¹, Biancarosa Volpe², Tomaso Bottio¹, Gino Gerosa¹

Affiliations

¹ Cardiac-Surgery-Unit, University of Padua, Padua, Italy.
² Psychological Unit, University of Padua, Padua, Italy.

PMID: 33734820
DOI: 10.1177/0391398821996726

Abstract

Left-ventricular-assist-device (LVAD) implantation in patients with antiphospholipid-syndrome (APS) is considered a high-risk procedure and its indication still represents an open challenge. Herein, we report a 63-year-old man with APS and end-stage heart failure, for whom a HeartMate3-LVAD and a continuous rheologic profile monitoring with a multiparametric assessment resulted the optimal therapeutic strategy.

Keywords: Left ventricle assist device; antiphospholipid antibody syndrome; hemocoagulation multi-monitoring system.

Publication types

Case Reports
Review

MeSH terms

Antiphospholipid Syndrome* / complications
Antiphospholipid Syndrome* / diagnosis
Antiphospholipid Syndrome* / therapy
Heart Failure* / etiology
Heart Failure* / therapy
Heart-Assist Devices*
Humans
Male
Middle Aged